Certain tests help find precise types of
cancer before signs or symptoms appear, called cancer screening. It main goal
is to reduce the number of people who develop the disease and reduce the number
of people who die from disease & prevent deaths from cancer altogether. It
involves urine tests, blood tests and medical imaging tests.
Some of the risk associated with cancer
screening are increased testing, false positives test results, over diagnosis
& over treatment and false reassurance.
According to study, “Europe
Cancer Screening Market (2018-2023)” the key companies operating in the
Europe cancer screening market are F. Hoffman-La- Roche Ltd, Johnson &
Johnson, Bayer AG, Pfizer Inc., Merck & co., Abbott Laboratories Inc.,
Becton, Dickinson and Company, Agilent Technologies, GE Healthcare, C. R. Bard,
Inc., Koninklijhe Philips N.V., Hologic Inc., Siemens Healthcare GmbH,
Illumina, Inc., Thermo Fisher Scientific Inc., Qiagen. Healthcare professionals
are focusing on expansion of effective screening solutions to check prevalence
level. Early detection rises the success rate of treatment regimens. As a
result, healthcare agencies & market players are promoting routine checkups
through various awareness programs.
Based on screening procedure, cancer screening
market is segmented into laboratory, imaging, biopsy, genetic, and endoscopy
tests. All screening procedures includes some tests such as breast
self-examination test, clinical breast examination test, Magnetic resonance
imaging (MRI), mammography and others. Mammography is a most common &
popular screening test employed for breast tumor screening. Based on genders,
market is segmented into men and women. Based on application, market is
segmented into lung, melanoma, kidney, breast, and colorectal cancer. Kidney
segment is projected to witness lucrative growth owing to rise in consumption
of tobacco & alcohol during the forecast period. In addition, based on
end-use, market is segmented into laboratories, hospitals, and independent
physicians & clinics.
The cancer screening market is driven by
increase in prevalence of cancer, followed by rise in adoption of a sedentary
lifestyle, increase in aging population, growth in focus of key players in the
emerging economies, rise in government investments for research &
development (R&D), improvement in healthcare infrastructure, and
healthcare, huge patient population, growth in technological advancements &
product innovations and change in environmental conditions. However, lack of
associated funding & transparency in medical procedures and stringent
regulations along with regulatory inter & intra state barriers may impact
the market. Moreover, rise in artificial intelligence and forthcoming health
revolution are key opportunities for market.
Based on geography, cancer screening market is
categorized as France, United Kingdom (UK) and Germany. It is estimates that
the market will be reached at rapid pace owing to increase in awareness about
cancer and rise in government initiatives for funding in the region. Various
organizations are undertaking many initiatives to spread awareness regarding
benefits of early detection, breast cancer, and available treatment options. It
is expected that future of the market will be bright due to rise in
availability of funds for research over the forecast period. The market is
anticipated to grow at a CAGR of approximately 8.1% resulting in an annual
revenue of US $22.43 billion during the forecast period (2018-2023).
For more information, click on the
link below:
Contact Us:
Ken Research
Ankur Gupta, Head Marketing &
Communications
+91
9015378249